OS Therapies Incorporated
OSTX · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $4 | $2 | $1 | $1 |
| G&A Expenses | $0 | $2 | $0 | $0 |
| SG&A Expenses | $3 | $2 | $4 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $7 | $5 | $5 | $3 |
| Operating Income | -$7 | -$5 | -$5 | -$3 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $1 | -$0 |
| Pre-Tax Income | -$7 | -$5 | -$4 | -$3 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$5 | -$4 | -$3 |
| % Margin | – | – | – | – |
| EPS | -0.21 | -0.18 | -0.18 | -0.04 |
| % Growth | -16.7% | 0% | -348.9% | – |
| EPS Diluted | -0.21 | -0.18 | -0.18 | -0.04 |
| Weighted Avg Shares Out | 32 | 25 | 21 | 124 |
| Weighted Avg Shares Out Dil | 32 | 25 | 21 | 124 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$4 | -$4 | -$3 |
| % Margin | – | – | – | – |